$ADIG

ADI Global Distribution (ADIG) insider sold $3.49M, plans more

ADI Global Distribution (ADIG) insider Jay Geldmacher filed a notice to sell up to 321,957 shares, following prior sales of 154,563 shares for $3.49M over three months. The sales are conducted through Morgan Stanley Smith Barney LLC.

Original reporting
Published Aug 21, 2026, 10:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 3:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ADIG
Bearish
medium confidence
Mentioned
$ADIG
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ADIGBearishLow
01

Why it matters

The disclosed sale size is modest, likely causing limited price movement unless aggregated with other insider sales.

02

Market read

Primary disclosure of insider sale; modest relevance for traders monitoring supply pressure on ADIG.

03

What to watch

Recent performance of ADIG and broader market sentiment may mitigate price impact.

Relevance 4/10Novelty 4/10Timing: post-market filing

Background

Form 144 filings are required for insiders to disclose planned sales of restricted shares, providing transparency on potential new share supply.

Company-level read

Ticker impact

$ADIGBearishMedium confidence
Context

Form 144 filing shows insider Jay Geldmacher plans to sell up to 321,957 shares (~$3.5M) of ADIG, increasing potential supply.

Expected impact

Modest downward pressure if sale proceeds quickly.

Evidence & confidence

Insider sales of several hundred thousand shares can signal reduced confidence and add supply, but the amount is modest relative to market cap.

Market effects

No immediate sector-wide impact; only affects ADIG supply dynamics.

Limited to US equity market where ADIG trades.

Low; micro‑cap insider sale has minimal global effect.

Counterpoint

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Jay Geldmacher

    ADIG insider filing Rule 144 notice.

Related articles

$ADIGMedAI 8/10

ADI GLOBAL DISTRIBUTION INC. (ADIG): Results of Operations and Financial Condition

ADI GLOBAL DISTRIBUTION INC. (ADIG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADI Announces Second Quarter 2026 Financial Results • Completed spin-off from Resideo; commenced trading on the NYSE on August 4, 2026 • Record net revenue of $1,286 million ; Commercial security growth returns to mid-single digits • Average daily sales growt h of 2%

$ADIGMed

Resideo Completes ADI Spin-Off as Distributor Begins Trading Independently

Resideo Technologies completed its spin-off of ADI Global Distribution, separating the wholesale distribution business into an independent NYSE-listed company. ADI began trading Aug. 4 under ticker ADIG, with shareholders receiving 1 ADI share for every 2 Resideo shares. Resideo repaid $900 million of Term Loan B principal and expects about $200 million more after a cash adjustment.

$FERGMed

Ferguson Enterprises To Replace Electronic Arts In S&P 500

S&P Dow Jones Indices, a division of S&P Global (SPGI), said Ferguson Enterprises (FERG) will replace Electronic Arts (EA) in the S&P 500 before the Aug. 5 open. EA is being acquired by an investor consortium including the Public Investment Fund, Silver Lake, and Affinity Partners, subject to final conditions. ADI Global Distribution (ADIG) will enter the S&P SmallCap 600, replacing Hertz (HTZ), after a Resideo (REZI) spin-off.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.